US Business News

AffirmedRx Believes Transparency Changes Everything in Pharmacy Benefits

For years, employers have been told that pharmacy benefit managers exist to help control the cost of prescription drugs. On paper, the model sounds straightforward: PBMs negotiate with drug manufacturers, manage pharmacy networks, process claims and help plan sponsors keep benefits affordable for employees.

However, inside one of the most complex corners of American healthcare, the question many employers are now asking is simple: If the system is designed to save money, why is it so hard to see where the money goes?

AffirmedRx was built to answer that question.

Founded in 2021 and headquartered in Louisville, Kentucky, AffirmedRx is a pharmacy benefit manager taking direct aim at one of the industry’s most entrenched problems: opacity. In a sector where rebates, spread pricing, network discounts and backend arrangements can make it difficult for plan sponsors to understand the true cost of their pharmacy benefit, AffirmedRx has positioned transparency not as a talking point, but as the foundation of its business model.

As employers increasingly search for AffirmedRx reviews and look for alternatives to traditional PBM models, the company has emerged as a name connected to transparency, patient advocacy and a different approach to pharmacy benefits.

“Transparency itself is not the end goal,” a company spokesperson said. “Rather, it is the means by which the end goals, increased trust in and accountability by PBMs, are achieved.”

That distinction is central to the company’s disruptive approach. AffirmedRx charges a flat administrative fee, passes savings back to clients and gives employers access to the kind of claim-level data many plan sponsors have historically struggled to obtain.

The company’s argument is not simply that employers deserve lower costs. It is that they cannot make informed decisions without a clear view of what they are paying for, where discounts are applied and whether drug choices are being driven by clinical value or hidden financial incentives.

In traditional PBM models, rebate dollars may be reported in aggregate, making it harder for employers to evaluate the true net cost of individual medications. That lack of visibility can shape formulary decisions, affect pharmacy access and leave plan sponsors guessing about whether the savings promised on the surface are actually reaching the people paying the bill.

AffirmedRx is pushing against that structure with a model designed around visibility, accountability and patient outcomes.

“Every dollar in savings flows directly back to the client,” a company spokesperson said.

Complete Claim-Level Transparency Changes The Conversation

Healthcare has spent years talking about transparency. Employers, however, often argue that what they receive is information, not understanding.

AffirmedRx believes there is a difference.

The challenge begins with how prescription drug pricing has historically worked behind the scenes. PBMs negotiate with drug manufacturers for price concessions by leveraging the bargaining power of the covered lives they represent. Those concessions often come in the form of rebates. A plan sponsor covers the drug’s list price at the pharmacy counter, minus any member cost sharing, and later receives rebate dollars intended to lower the true cost of that prescription.

The structure can sound like a logical cost-reduction strategy. In practice, it can also create opportunities for non-transparent PBMs to retain a portion of price concessions as revenue. As calls grew for 100% pass-through of rebates, some large PBMs began using more complicated arrangements, including affiliated group purchasing organizations, to negotiate and route rebate dollars before they reached health plans.

That kind of structure can obscure the true flow of money.

Some high-cost medications carry significant rebates while others do not. Some savings appear in broad reporting rather than being connected to specific medications or individual claims. Without claim-level data, employers may struggle to determine whether the lowest-cost option is truly the best option after rebates, discounts and acquisition costs are considered.

AffirmedRx has built its model around removing those blind spots.

Rather than presenting employers with broad snapshots after decisions have already been made, the company gives plan sponsors claim-level visibility designed to show where dollars are moving in real time.

“Complete claim-level data transparency is essential,” a company spokesperson said.

The company believes transparency changes behavior. Formulary decisions become more intentional, cost forecasting becomes more predictable and accountability becomes measurable rather than assumed.

When Transparency Reaches The Patient

Transparency does not stop with employers and plan sponsors. The company’s model is also designed to reach the person standing at the pharmacy counter waiting to find out whether a medication is covered, affordable and available.

That is where AffirmedRx’s patient-centric service model enters the picture.

Patient Care Advocates work directly with members, providers and pharmacies to identify savings opportunities, resolve access barriers and help people navigate a system that can feel overwhelming.

“Patient-centric means putting the experience and needs of the plan member at the heart of every business decision,” a company spokesperson said.

The difference, according to the company, is proactivity.

Rather than waiting for a frustrated member to call after a denied claim, Patient Care Advocates have access to real-time claims information and can intervene before patients arrive at the pharmacy counter.

In one case, an advocate assisted a member relying on a specific seizure medication after an alternative option created serious clinical concerns. The advocate researched pharmacy options, escalated the issue internally and maintained communication with the member until a long-term override was secured through 2026.

Transparency becomes more powerful when it moves beyond spreadsheets and into real-world moments that affect a person’s health.

A Public Benefit Corporation With A Different Incentive Model

AffirmedRx also stands apart because of how it is structured.

The company is the only pharmacy benefit manager organized as a Public Benefit Corporation, a designation that allows leadership to prioritize broader stakeholder outcomes alongside business performance.

That structure aligns with the company’s emphasis on 100% pass-through pricing and total transparency. Rather than generating revenue through hidden streams or spread pricing arrangements, the company says incentives should remain aligned with employers and members.

The model reflects a broader shift happening across healthcare where organizations are increasingly asking whether success should be measured only by financial performance or also by the outcomes delivered to people.

Affirmedrx Reviews Reinforce The Transparency Story

Transparency in pharmacy benefit management is not just a business principle. It shapes how people experience healthcare.

AffirmedRx’s approach has earned URAC Accreditation for Pharmacy Benefit Management, a designation that validates operational quality and performance standards. Yet much of the company’s story appears in the experiences shared by members themselves.

“Our employer switched benefits managers to Affirmed this year, and the transition was seamless,” a reviewer named Lucas wrote. “We had a question about the cost of a specialty medication, and the rep we worked with was very responsive and helpful.”

Reviewer Eric N. described a different kind of impact after his employer moved to AffirmedRx.

“When my employer switched to AffirmedRx, suddenly meds not being covered or needing a PA disappeared,” Eric wrote. “I dealt with a terrible PBM for years, not having any recourse or say in the matter. It’s so nice not to have to anymore.”

Members have also reported positive experiences with the AffirmedRx Pulse app, noting that the platform has helped lower out-of-pocket prescription costs and simplify the process of managing benefits.

Taken together, those experiences reveal something larger than customer satisfaction. They point toward a model built around visibility, human support and accountability.

The healthcare industry has spent years trying to untangle rising drug costs and growing frustration around pharmacy benefits. Employers want better cost predictability. Members want easier access to medication. Pharmacies want fair treatment. Plan sponsors want to know whether the dollars they spend are being used in the best interest of their people.

AffirmedRx is making the case that those goals are connected.

By centering transparency, claim-level data, 100% pass-through pricing and patient advocacy, the company is challenging an industry long shaped by complexity. Its argument is simple but consequential: pharmacy benefits work better when the people paying for care can see what they are paying for, and when the people depending on care are not left to navigate the system alone.

 U.S. Chip Manufacturing Efforts Gain New Industry Support

Domestic semiconductor production remains at the center of new industrial development plans after a manufacturing collaboration involving major technology and chipmaking interests was announced in the United States. The initiative focuses on expanding production capacity for advanced semiconductors within the country and brings together organizations seeking to strengthen local manufacturing capabilities for critical electronic components.

The announcement follows continued efforts by government agencies, manufacturers, and technology companies to increase the availability of domestically produced chips used in consumer electronics, artificial intelligence systems, communications equipment, automotive technology, and industrial applications. Industry participants stated that additional manufacturing cooperation is intended to support long-term production goals while reducing dependence on overseas fabrication facilities.

Domestic Semiconductor Production Capacity Expands Through New Collaboration

The newly announced collaboration centers on increasing semiconductor manufacturing activity within the United States through coordination between technology developers and domestic production facilities. Participants indicated that the arrangement is designed to support fabrication capacity for advanced chips while utilizing existing manufacturing infrastructure and future facility investments.

Semiconductors serve as essential components in a wide range of products, including smartphones, computers, cloud computing systems, networking equipment, vehicles, medical devices, and defense technologies. The ability to manufacture these components domestically has become a strategic priority for both public and private sector organizations.

Manufacturing expansion plans include efforts to improve production efficiency, increase output capabilities, and support future technology requirements. Industry representatives stated that collaboration between chip designers and manufacturing facilities can help accelerate production timelines while creating opportunities for additional investment in domestic operations.

The latest announcement reflects ongoing efforts to establish a stronger semiconductor supply chain within the United States. Manufacturers have continued evaluating production strategies that allow more advanced chips to be fabricated closer to end markets and major customers.

Federal initiatives supporting semiconductor manufacturing have also encouraged companies to consider additional domestic investments. Several large-scale fabrication projects announced in recent years remain under construction or are progressing through various stages of development across multiple states.

Semiconductors Remain Critical to Multiple U.S. Industries

The importance of semiconductor manufacturing extends beyond the technology sector. Chips are integrated into products used throughout the economy, making their availability a significant factor for manufacturers across numerous industries.

Automotive producers rely on semiconductors for vehicle control systems, safety features, navigation platforms, sensors, and electric vehicle technologies. Consumer electronics manufacturers require advanced processors and memory components to support new products entering the market.

Industrial equipment companies increasingly incorporate sophisticated semiconductor technologies into automation systems, robotics, and monitoring equipment. Healthcare providers and medical device manufacturers also depend on reliable semiconductor supplies for diagnostic tools, imaging systems, and connected medical technologies.

Demand for advanced computing infrastructure has further increased the need for high-performance semiconductors. Artificial intelligence applications, cloud computing services, and data center operations require substantial processing power supported by specialized chips.

Industry executives have stated that maintaining access to reliable semiconductor supplies remains a priority as technology requirements continue expanding across multiple sectors. Domestic manufacturing initiatives are intended to provide additional production resources capable of supporting future demand.

Production facilities located in the United States can also offer advantages related to logistics, supply chain management, and coordination between manufacturers and customers. Shorter transportation routes may reduce delivery times and improve responsiveness to changing market requirements.

Federal Support Continues to Shape Manufacturing Investment

Federal policy initiatives have played a significant role in encouraging semiconductor investment throughout the country. Legislative measures and incentive programs introduced during the past several years have provided financial support for manufacturing projects, research activities, workforce development efforts, and supply chain initiatives.

Government officials have repeatedly identified semiconductor production as a strategic industry due to its importance to economic activity, national security, technological development, and industrial competitiveness. Multiple agencies have participated in programs intended to increase domestic production capabilities.

Funding opportunities have encouraged manufacturers to evaluate new facility construction projects and expansion plans. Companies have announced investments in fabrication plants, packaging facilities, research centers, and supporting infrastructure in response to available incentives.

State governments have also participated in efforts to attract semiconductor-related projects. Economic development programs, workforce training partnerships, infrastructure improvements, and tax incentives have been utilized to support manufacturing investments.

Several regions have emerged as significant semiconductor hubs due to the concentration of facilities, suppliers, universities, and technical talent. States including Arizona, Texas, Ohio, and New York have attracted substantial investment commitments connected to semiconductor production and research activities.

Industry participants have noted that manufacturing projects often require extensive planning and construction timelines. Advanced fabrication facilities represent some of the most complex industrial developments undertaken within the manufacturing sector and require significant capital investment before production begins.

Technology Companies Seek Greater Supply Chain Resilience

Supply chain considerations continue to influence semiconductor manufacturing strategies across the technology industry. Companies have increasingly examined production networks to identify opportunities for improving resilience and reducing potential disruptions.

Semiconductor supply challenges experienced during recent years affected industries ranging from automotive manufacturing to consumer electronics. Production delays and component shortages demonstrated the importance of maintaining reliable access to chip supplies.

Manufacturers responded by reevaluating sourcing strategies and considering additional production locations. Some companies entered long-term supply agreements, while others pursued investments designed to expand manufacturing capacity closer to key markets.

Domestic production initiatives are intended to complement existing global manufacturing networks rather than replace them entirely. Industry participants continue to operate within an international supply chain that includes design, fabrication, testing, packaging, and distribution activities occurring in multiple regions.

The latest collaboration announcement reflects ongoing efforts to strengthen manufacturing capabilities while supporting customer requirements for advanced semiconductor technologies. Companies involved in chip production continue to seek approaches that balance efficiency, capacity, and supply chain stability.

Executives have indicated that partnerships between technology developers and manufacturing organizations can help align production plans with future product requirements. Coordination between these groups may support faster deployment of new semiconductor technologies while expanding manufacturing output.

Elevation Publishing Group Takes a New Approach to Modern Publishing

By: Sebastian Clarke

Most publishing companies ask authors to fit into their model. Elevation Publishing Group was built to do the opposite.

Founded by DeVasha Lloyd, a New York City executive with over two decades of experience across media, healthcare, and publishing, Elevation Publishing Group is a boutique hybrid publisher operating on a philosophy that is straightforward but genuinely uncommon in the industry: the author comes first, the strategy comes with it, and the book is only the beginning of the conversation.

What Hybrid Publishing Actually Means Here

The hybrid model has become a crowded term in publishing, used by companies with very different levels of service and very different commitments to the authors they work with. At Elevation Publishing Group, it means something specific.

Authors retain 100 percent of their rights. They keep 100 percent of their royalties. They have full creative control over every element of the book, from cover design to final edits. And they have access to a professional team that includes experienced ghostwriters, editors, designers, and marketing partners who treat the project with the same seriousness a major imprint would, but without the delays, limitations, or loss of ownership that traditional publishing often requires.

The timeline matters too. Elevation Publishing Group gets books to market in four to six months, even for authors who begin the process without a completed manuscript. In a content environment where timing can be the difference between relevance and irrelevance, speed is a genuine competitive advantage.

More Than a Publisher

What separates Elevation Publishing Group from most of its competitors isn’t just the model. It’s the mindset behind it.

DeVasha built her career understanding that content without strategy is noise. She spent years helping some of the most recognized brands in healthcare and media figure out not just what to say, but how to say it, where to say it, and how to turn a single piece of content into a sustained platform. That expertise flows directly into how Elevation Publishing Group works with authors.

A book published through Elevation Publishing Group isn’t just produced and distributed. It’s positioned. The team works with each author to build a strategy that extends beyond the printed page, connecting the book to speaking opportunities, media visibility, digital content, and the kind of long-term audience growth that can extend a single title into a lasting platform.

For authors who publish under their own business brand name as a white-label imprint, that positioning becomes even more powerful. The book doesn’t just represent their ideas. It represents their authority.

A Partnership That Opens Bigger Doors

Elevation Publishing Group’s relationship with Forbes Books gives select clients access to one of the most recognized publishing imprints in the world. For thought leaders, executives, and entrepreneurs who want the credibility that comes with a Forbes association alongside the personalized attention of a boutique publisher, that combination is genuinely rare.

DeVasha’s track record at Forbes Books, where she personally published over 80 titles for top executives and industry leaders, means she understands exactly how to position an author for that level of visibility and what it takes to make it stick.

What Authors Actually Need

The publishing industry has never been more crowded. Millions of titles enter the market every year. The vast majority struggle to find readers, not because they lack quality but because they lack strategy.

Elevation Publishing Group exists to close that gap. One carefully developed, thoughtfully positioned, professionally produced book at a time.

For authors who are ready to stop thinking about their book as a project and start thinking about it as a platform, Elevation Publishing Group structures its work around an initial discovery conversation.

Because the difference between a book that exists and a book that matters almost always comes down to what happens after it’s released.

Discover more about DeVasha Lloyd and the vision behind her work at Elevation Publishing Group.

How Ensemblab Emerged Amid Growing Global Interest in Artificial Intelligence, Enterprise Automation, and Digital Transformation

The field of artificial intelligence has evolved from an academic area of study into a business area of concern in many parts of the globe. Companies are looking at the use of artificial intelligence technology for making decisions, knowledge management, workflow processes, and increased efficiency. The artificial intelligence market is expected to go from $189 billion in 2023 to $4.8 trillion in 2033, according to UN Trade and Development (UNCTAD). This shows the extent of the growth that artificial intelligence technology is experiencing worldwide.

Despite the rising level of interest, the adoption process is not yet complete. According to research conducted by McKinsey in 2025, 88 percent of the organizations surveyed have been employing AI in at least one functional area of their organization. Nevertheless, many organizations were still at the experimental or pilot stage rather than running full-blown AI initiatives. Furthermore, the research conducted by McKinsey showed that more organizations had become interested in deploying AI agents and autonomous systems. Many organizations still needed to figure out how best to integrate such systems into their operations.

It was within this broader environment that Ensemblab was established in Pakistan in 2024. Founded by a group of Pakistan-based entrepreneurs, the company was created as a technology firm focused on artificial intelligence, enterprise technology, digital transformation, and automation. Its stated objective was to develop AI-driven systems that could support organizations in managing operational processes, decision-making activities, compliance requirements, and knowledge management functions. Since its formation, the company has positioned its work around the application of AI technologies to enterprise environments rather than consumer-focused products.

According to company information, Ensemblab’s activities are centered on enterprise automation and organizational intelligence systems. The company develops software and services intended to support workflow automation, business process optimization, and operational management. These efforts reflect a wider trend within the technology sector, where organizations increasingly seek tools capable of reducing manual workloads while improving access to information and analytical capabilities. Industry discussions have increasingly focused on the challenge of integrating AI into existing processes without creating additional operational complexity.

A significant part of Ensemblab’s work is connected to enterprise artificial intelligence platforms. The company states that its systems are designed to assist organizations with research, operational support, automation, and decision-making activities. Platforms of such a nature have increasingly attracted attention because companies try to go further from the point of isolated AI projects to the integration of technologies. Surveys reveal that there are a lot of problems regarding the governance, monitoring, and estimation of the long-term value of such initiatives on behalf of organizations.

Also, the corporation mentions Agentic AI among its main priorities. Usually, agentic AI can be regarded as those systems that can perform some tasks or help people with certain operations to a greater or lesser extent. According to McKinsey (2025), as many as 62% of companies were already implementing or even researching this technology in 2025. Ensemblab’s agentic systems are described as tools intended to support research activities, planning functions, operational tasks, and workflow execution within organizational settings.

Another area of development involves digital twin technology. Digital twins are virtual representations of assets, processes, or operational environments that can be used for monitoring and analysis. According to company materials, Ensemblab develops digital twin systems designed to model organizational activities and provide greater visibility into operations. The company’s CADET platform, short for Continuous Audit Digital Enforcement Twin, is presented as a compliance-focused digital twin intended to support monitoring, auditing, and regulatory processes through automation and AI-assisted analysis.

Regulatory technology, often referred to as RegTech, represents another component of the company’s activities. Organizations across many sectors continue to face increasing compliance obligations and reporting requirements. Ensemblab states that it develops Governance, Risk, and Compliance software intended to assist organizations with compliance monitoring and risk management activities. Recent surveys have suggested that governance remains a significant concern as AI adoption expands. An IBM study released in 2026 reported that many technology leaders believe existing governance frameworks are not fully prepared for the large-scale deployment of AI systems.

In addition to operational technologies, Ensemblab has developed systems focused on knowledge management and information access. The company identifies Retrieval-Augmented Generation, commonly known as RAG, as one of its technical areas. These systems combine information retrieval methods with generative AI models in order to support research and enterprise knowledge functions. The company also develops digital onboarding solutions intended to automate customer and employee onboarding processes through workflow management and AI-assisted verification.

Alongside software development, Ensemblab publishes educational and technical content through its online knowledge base.

While AI is continuously advancing in various sectors of the economy, businesses are considering different ways to apply this technology. Ensemblab can be seen as one of the tech companies formed in the wake of the AI revolution. From the time it was founded in 2024 by a team of Pakistani entrepreneurs, Ensemblab has been committed to developing enterprise AI platforms, agentic AI, digital twins, regtech, KM systems, and automation solutions. Whether or not this technology becomes popular in most organizations is yet to be determined.